PUNE, India, October 9, 2015 /PRNewswire/ --
According to the Pulmonary Hypertension - Global Market Research 2015-2019 report, hypertension treatment is shifting toward the use of combination therapies that employ two or more drugs and it may result in better outcomes for the industry.
Complete report on pulmonary hypertension market spread across 65 pages, analyzing 4 major companies and supported with 33 data exhibits is now available at http://www.reportsnreports.com/reports/426973-pulmonary-hypertension-global-market-research-2015-2019.html .
Combination therapy with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. The treatment is also aimed at targeting various disease mechanisms that may result in better outcomes for the pulmonary hypertension market. According to this report, the median survival for a person living with pulmonary hypertension is only five to six years. In addition, the current treatments do not target the underlying cause of the disorder. Thus, the disorder treatment is associated with poor patient compliance. Hence, patients often discontinue the treatment without completing the treatment cycle. Other classes (or types) of medications used to treat pulmonary hypertension also have side effects.
Current treatment options result in unmet medical needs that warrant the development of new drugs with better safety and efficacy, thereby driving the pulmonary hypertension market. Further, the report states that patent expiry of drugs such as Revatio is hindering the market growth by allowing low-cost generics to enter the market. Poor patient compliance during treatment due to the adverse effects of the drugs used is also impeding the pulmonary hypertension market growth. To calculate the market size, this research considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.
Actelion, Bayer, GlaxoSmithKline, United Therapeutics, Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer and PhaseBio are the companies mentioned in Pulmonary Hypertension - Global Market Research 2015-2019 report available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=426973 .
Some of the data exhibits provided in this pulmonary hypertension market research include:
Product offerings
Global pulmonary hypertension market: 2014-2019 ($ billions)
Five forces analysis
Pipeline portfolio
Market segmentation by type of formulation
Market segmentation by type of formulation 2014
Market segmentation by mechanism of action
Market segmentation by mechanism of action 2014
Market segmentation by region 2014
Impact of drivers
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.
The second research titled Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline is spread across 82 pages and says over the 2014-2021 forecast period, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is projected to vary considerably across the four assessed markets. This report discusses marketed products including Prestalia (perindopril arginine + amlodipine besylate), Azilva (azilsartan medoxomil), Amlodipine besylate, Telmisartan, Aliskiren, Olmesartan medoxomil, Valsartan, Losartan and Exforge (amlodipine + valsartan). SER-100 and CS-3150 are the promising drug candidates in pipeline covered in the report available at http://www.reportsnreports.com/reports/411426-anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2021-increasing-prevalence-of-hypertension-drives-market-growth-despite-weak-pipeline.html .
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Pinterest: www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com
SOURCE ReportsnReports
